{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Chelator Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Experimental Therapy Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_5",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_6",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_7",
        "name": "Outpatient Dosing Time Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_8",
        "name": "Post-Dose Fasting",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2
      },
      {
        "id": "timing_9",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_10",
        "name": "Enrollment Day",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_11",
        "name": "Inpatient Period 1",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_12",
        "name": "Inpatient Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_13",
        "name": "Alcohol Abstinence Period",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48
      },
      {
        "id": "timing_14",
        "name": "Tetrathiomolybdate Washout Period",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Safety Review for Dose Titration",
        "instanceType": "Condition",
        "description": "Safety data must be reviewed by the Safety Review Committee before dose titration.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Neutropenia Criteria for Dose Modification",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to low neutrophil count.",
        "text": "Neutrophils > 30% ↓ from baseline and below reference range at baseline."
      },
      {
        "id": "cond_3",
        "name": "Liver Injury Criteria for Dose Modification",
        "instanceType": "Condition",
        "description": "Criteria for temporary dose interruption due to potential liver injury.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury."
      },
      {
        "id": "cond_4",
        "name": "Neurologic Worsening for Dose Modification",
        "instanceType": "Condition",
        "description": "Evaluation of neurologic worsening to determine need for dose modification.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment."
      },
      {
        "id": "cond_5",
        "name": "Psychiatric Worsening for Dose Modification",
        "instanceType": "Condition",
        "description": "Evaluation of psychiatric worsening to determine need for dose modification.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_6",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "Adaptive design feature allowing for extension of the outpatient period.",
        "text": "To ensure flexibility, the Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      },
      {
        "id": "cond_7",
        "name": "Rechallenge Limit",
        "instanceType": "Condition",
        "description": "The maximum number of times a participant can be rechallenged with the study drug after a dose modification.",
        "text": "A maximum of 3 rechallenges will be allowed."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_2",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Reduce dose to previous dose level if up-titration has occurred or reduce dose to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_3",
        "name": "Dose Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Temporary interruption for Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN."
      },
      {
        "id": "trans_4",
        "name": "Dose Modification for Neurologic Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on copper control parameters and relevant clinical data."
      },
      {
        "id": "trans_5",
        "name": "Discontinuation for Serious Hypersensitivity",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if a Serious hypersensitivity reaction occurs."
      },
      {
        "id": "trans_6",
        "name": "Discontinuation for Severe Infection",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if a Severe uncontrolled infection occurs."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for Use of disallowed medication."
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for Pregnancy or planned pregnancy."
      },
      {
        "id": "trans_9",
        "name": "Dose Titration Hold",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "participants may remain on the 15 mg/day dose for the duration of the study if there are safety concerns."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination of Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of Alexion."
      },
      {
        "id": "exit_6",
        "name": "Site Closure",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Reasons for the early closure of a study site by Alexion or Investigator may include but are not limited to: Failure of the Investigator to comply with the protocol, Inadequate recruitment of participants, Discontinuation of further study intervention development."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 23",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for the Safety Review Committee to approve dose titration from 15 mg/day to 30 mg/day based on safety data review through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Dose Modification Decision for Safety Event",
        "timepointId": "Unscheduled",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for dose modification (reduction, interruption) based on the occurrence of specified safety events like neutropenia, liver injury, or neurologic/psychiatric worsening.",
        "conditionIds": [
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5"
        ]
      },
      {
        "id": "dec_3",
        "name": "Outpatient Period Extension Decision",
        "timepointId": "During Outpatient Period",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision by the Investigator to extend the outpatient period by up to 14 days.",
        "conditionIds": [
          "cond_6"
        ]
      }
    ],
    "summary": {
      "timingCount": 14,
      "conditionCount": 7,
      "transitionRuleCount": 9,
      "exitCount": 6
    }
  }
}